Lakeside
Distributes pharmaceutical and medical products in China through Hupan Pharmaceutical.
Something off on this page? Send us feedback.
Profile
Distributes infusion products, specialty prescription drugs, and medical-nutrition products in China through Hupan Pharmaceutical. Revenue comes from product sales to hospitals, distributors, clinics, and other health-care providers, with pharmaceutical distribution as the sole continuing operating segment.
Distributes infusion products, specialty prescription drugs, and medical-nutrition products in China through Hupan Pharmaceutical (Hubei) Co., Ltd., which operates from Wuhan within a Nevada holding-company structure headquartered in Itasca, Illinois. The unit buys from manufacturers, holds products at designated warehouses, and delivers them to hospitals, distributors, clinics, and other health-care providers, often through agents.
Generates revenue from product sales, with manufacturer costs net of discounts and rebates forming cost of revenue. The continuing business depends on pharmaceutical-operation licensing, market-regulation and drug-administration inspections, government bidding and procurement practices, supplier access, customer relationships, and working-capital timing between receivables, supplier terms, and inventory prepayments. It is the sole reportable and continuing operating segment following the disposal of the former logistics subsidiary.
Company facts
Key statistics
Year to date −53.3% · Average volume (30d) 7.7M
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| May 19, 2026Q3 FY26 | — | −$0.04 | — | — | $1.3M | — | −2.33% |
| Feb 19, 2026Q2 FY26 | — | −$0.08 | — | — | $7.0M | — | +9.82% |
| Nov 19, 2025Q1 FY26 | — | −$0.09 | — | — | $6.1M | — | −1.48% |
| Oct 14, 2025Q1 FY26 | — | −$0.11 | — | — | $6.3M | — | +8.27% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $3.6M | $3.8M | $6.3M | $6.1M | $7.0M | $1.3M | |
| Gross profit | −$42.2K | $715.9K | $1.8M | $1.1M | $1.9M | $979.5K | |
| Operating income | −$2.0M | −$1.1M | −$556.8K | −$1.3M | −$1.5M | −$1.6M | |
| Net income | −$1.9M | −$1.1M | −$893.1K | −$1.4M | −$1.6M | −$1.5M | |
| Diluted EPS | −$0.26 | −$0.14 | −$0.11 | −$0.09 | −$0.08 | −$0.04 | |
| Gross margin | -1.2% | 18.8% | 28.3% | 18.2% | 27.2% | 73.8% | |
| Operating margin | -55.6% | -28.2% | -8.8% | -20.8% | -21.3% | -118.7% |
Fiscal years (4-quarter sums)FY23 $12.9M · FY24 $18.3M · FY25 $17.8M
Revenue by geography · Q2 FY26
Balance sheet, Mar 31, 2026Cash & short-term investments $1.3M · Total debt $561.6K · Total assets $17.8M · Shareholders' equity $13.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 34.43M · Float 25.78M
Insiders — no current Form 4 position.
This issuer lists more than one class and the share count spans them all, so a stake here reads as a share of the whole company, not of this class.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % of company | Form | Filed |
|---|---|---|---|---|
| Brink Holding Limited | 2.04M | 8.57% of class | 13G | May 4, 2026 |
| Vanguard Capital Management LLC | 295.7K | 0.86% | 13F | May 15, 2026 |
| Geode Capital Management, LLC | 172.2K | 0.50% | 13F | May 15, 2026 |
| Vanguard Fiduciary Trust Co | 135.1K | 0.39% | 13F | May 8, 2026 |
| Goldman Sachs Group Inc | 56.0K | 0.16% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
Not reported.